08/4/20

7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies

08/3/20

Opinion: Warp Speed to a united or divided America? COVID-19 vaccine trials must include at-risk groups

11/01/21

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

06/8/20

7 Hills Pharma Receives $3.5M to Continue Development Of Integrin Activators to Augment Immunotherapies

11/09/20

7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

12/7/20

7 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness

08/28/20

Barda Enlisting Start-Ups In Fight Against COVID-19 Via JLABS Collaboration

06/15/20

7 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference

09/17/20

7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines

04/14/20

7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant  

​

​09/14/21

​Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research

Media​

09/5/20

7 Hills Pharma to Participate in Johnson & Johnson Innovation's BLUE KNIGHT™ Collaboration with U.S. Government for its Efforts to Combat COVID-19

10/28/20

7 Hill Pharma Names William Schary VP of Clinical & Regulatory Affairs

03/21

IMMUNE ACTIVATORS – Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies

​04/15/20

7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly​

07/7/20

7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines

03/08/22

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

12/8/20

Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19

11/17/20

7 Hills Pharma Receives Orphan Drug Designation for Lead Product, 7HP349, in Treatment of Malignant Melanoma

06/4/20

7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12

07/26/21

7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers